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Viral membranePreviously we reported that hydrophobic aryl azides partition into hydrophobic regions of the viral
membrane of enveloped viruses and inactivate the virus upon UVA irradiation for 2 min. Prolonged irradiation
(15 min) resulted in viral protein aggregation as visualized via Western blot analysis, due to reactive oxygen
species (ROS) formation, with preservation of the surface antigenic epitopes. Herein, we demonstrate that
these aggregates show detergent resistance and that this property may be useful towards the creation of a
novel orthogonal virus inactivation strategy for use in preparing experimental vaccines. When ROS-modiﬁed
HIV virus preparations were treated with 1% Triton X-100, there was an increase in the percent of viral
proteins (gp41, p24) in the viral pellet after ultracentrifugation through sucrose. Transmission electron
microscopy (TEM) of these detergent-resistant pellets shows some recognizable virus fragments, and
immunoprecipitation studies of the gp41 aggregates suggest the aggregation is covalent in nature, involving
short-range interactions.enthal).
esda, Bethesda, Maryland, USA.
Inc.Published by Elsevier Inc.Introduction
There is a continuing need for safe, effective vaccines against
existing and emerging viral threats. Novel vaccine preparation
strategies that are broadly applicable to a variety of viruses are
desirable. One such method, referred to as an inactivated or “killed”
virus vaccine, uses an infectious viral preparation that is renderednon-
infectious through chemical, thermal or othermeans. The advantage of
this technique is that after inactivation, the virus ismostly intact and is
able to present epitopes similar to that of the infectious virus to the
immune system. This strategy is currently used in the United States for
the preparation of certain inﬂuenza, Hepatitis A and Polio vaccines.
While this method has met with success, there is data supporting that
somemethods of inactivation damage surface epitopes (Adler-Storthz
et al., 1983; Bachmann et al., 1994; Duque et al., 1989; Grovit-Ferbas
et al., 2000; Poon et al., 2005; Sattentau, 1995; Tano et al., 2007).
Additionally, there are still reasonable concerns over the safety of such
amethod (Brown, 1993), especiallywhen it is applied to novel viruses.
It is generally accepted that ~15 logs of inactivation are needed tocreate a vaccine that is reasonably safe (Schultz et al., 1990; Sheppard,
2005). This requirement for inactivation pushes the limits of detection
of most assays and can be difﬁcult to achieve with one inactivation
method alone.
A strategy that we are developing for the inactivation of enveloped
viruses uses photoactivatable hydrophobic molecules that selectively
target the hydrophobic region of the viral membrane. In particular,
azidonaphthalene compounds, such as 1,5-iodonaphthyl azide (INA),
partition selectively into the hydrophobic region of the viral mem-
brane (Bercovici and Gitler, 1978), and can be photoactivated using
UVA irradiation to rapidly (2 min of irradiation) inactivate the virus.
Photoactivation of INA in puriﬁed viral preparations has been shown to
result in the inactivation of various enveloped viruses, such as Ebola,
inﬂuenza, HIV, and VEEV, with preservation of key surface epitopes,
and, in the case of inﬂuenza, enhanced immunogenicity (Belanger
et al., 2010; Raviv et al., 2008; Raviv et al., 2005; Sharma et al., 2007;
Warﬁeld et al., 2007). In the case of HIV, using a sensitive cell-based
p24 assay, it was shown that INA-inactivation resulted in at least 4 logs
of inactivation (Raviv et al., 2005). It was also discovered that
prolonged UVA irradiation (15 min irradiation time) in the presence
of INA or other arylazides resulted in the formationof highermolecular
weight viral protein aggregateswhenviral lysatewas characterized via
Western blot analysis (Belanger et al., 2010). These aggregates were
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that viral inactivation occurs through the binding of the azido moiety
and that these ROS-induced aggregates, while not needed for viral
inactivation, did not result in thedamageof surface epitopes andmight
therefore be advantageous towards the creation of a novel vaccine
strategy, described herein. While this INA-inactivation technique has
been shown to be rapid and applicable to a variety of enveloped
viruses, it still results in an inactivated viral preparation in which
15 logs of inactivation is difﬁcult to prove.
To ensure greater than 15 logs of viral inactivation in inactivated
virus preparations, it is generally accepted that multiple methods of
inactivation are needed that operate on mechanisms independent of
each other, and each produce 6–8 logs of inactivation (Schultz et al.,
1990). Such “orthogonally inactivated” vaccines have the additive
effect of each inactivation technique to meet the required 15 logs of
inactivation. However, each additional treatment step may result in
the destruction or modiﬁcation of the native virus, and result in the
loss of key epitopes needed to elicit an effective immune response.
Indeed, when “split” virus vaccines are made, orthogonal inactivation
methods are used (viral inactivation typically followed by detergent
treatment), but result in vaccine preparations containing soluble viral
proteins (see Fig. 1A). For example, in some inﬂuenza vaccine
preparations, virus is inactivated and subsequently treated with a
non-ionic detergent to “split” the virus, followed by puriﬁcation to
remove the detergent and isolate the solubilized viral proteins
(hemagglutinin, for inﬂuenza). While this preparation is “orthogonal”
and safe, it no longer consists of intact virus particleswhich is the form
encountered by the host in nature, and undoubtedly many epitopes
associated with the native virion are lost.
Although traditional “split” vaccines have proven to be effective, it
has been shown that whole inactivated inﬂuenza vaccines are more
immunogenic than split or subunit vaccines (Cox et al., 2006;
Geeraedts et al., 2008). With this in mind, we propose a novel vaccine
strategy in which orthogonal methods are used for viral inactivation,
with preservation of viral protein aggregates that represent key viral
antigens. Herein, infectious puriﬁed virus is inactivated through
chemical means using photoactivatable aryl azides, which, in addition
to inactivation, renders the virus partially detergent resistant.
Subsequent treatment with detergent results in a partially split
virus vaccine preparation that contains viral aggregates of key viral
proteins in the viral lysate (see Fig. 1B), unlike traditional split virus
vaccines that contain soluble proteins (see Fig. 1A). This method is not
virus-speciﬁc and can be applied to other enveloped viruses as well.
Herein, we describe the characterization of such detergent resistance
as applied to an enveloped virus, human immunodeﬁciency virus
Type 1 (HIV-1).Fig. 1. A proposed novel approach for orthogonally inactivated virus vaccine preparation us
preparation of “traditional” inactivated split virus vaccine resulting in solubilized proteins. B)
induced protein aggregation to form detergent-resistant viral protein aggregates. Inset of HI
other viral proteins (all other colored circles and sticks).Results and discussion
It has been shown that treatment of HIV-1, and other enveloped
viruses, with hydrophobic aryl azides plus UVA irradiation resulted in
inactivation of the virus within 2 min, without damage to the surface
epitopes, making such a preparation a viablemethod for the generation
of inactivated virus vaccines (Belanger et al., 2010; Raviv et al., 2008;
Raviv et al., 2005; Sharma et al., 2007; Warﬁeld et al., 2007).
Additionally, it was found that treatment of HIV-1 with aryl azides
and prolonged UVA irradiation (15 min) resulted in the formation of
higher molecular weight aggregates as seen on Western blot analysis
which were a result of reactive oxygen species (ROS) formation
(Belanger et al., 2010). The formation of these protein aggregates was
eliminated by using methods to scavenge the radicals formed or to
oxygen deplete the system during treatment, resulting in an infectious
viral preparation free of detectable aggregates. Interestingly, these
protein aggregates are recognized by the antibodies used for Western
blot detection and can be captured using neutralizing antibodies
(Belanger et al., 2010). These protein aggregates were not dissociated
under the conditions of SDS-PAGE, which uses SDS (an ionic detergent)
to solubilize proteins. Herein, this “detergent resistance” was charac-
terized using Western blot, ultracentrifugation, immunoprecipitation
and electron microscopy to further understand the mechanism of this
detergent resistance and it's applicability towards the generation of a
novel orthogonally inactivated virus vaccine strategy.
UV-activated aryl azide treatment of HIV-1 causes detergent insoluble
fragments
Using either INA or DAN followed by UVA irradiation for 15 min
resulted in protein aggregates that persisted under the denaturing and
reducing conditions of SDS-PAGE.Western blotting indicated that these
aggregates contained key viral proteins that although aggregated, were
still recognized by the antibodies used for immunostaining (see Fig. 2,
and reference (Belanger et al., 2010)). These detergent insoluble
aggregates contained the transmembrane proteins (gp41), as well as
the capsid protein (p24), and matrix protein (p17). The surface protein
(gp120),which is hydrophilic and heavily glycosylated, does not appear
in this highermolecularweight smear. This lack of aggregation in gp120
can possibly be attributed to the protection of the protein against ROS
damage due to heavy glycosylation (Uchida et al., 1997).
The exact mechanism of this protein aggregation remains unclear,
although it is directly related to ROS that are induced from UVA
irradiation of the azido compounds. These aggregated proteins are
only produced in systems where aryl azides are used, suggesting that
a side-product of the chemical inactivation is the production ofing detergent insoluble viral protein aggregates. A) Generalized typical pathway for the
Proposed “novel” orthogonal inactivation strategy using reactive oxygen species (ROS)
V depicts lipids (purple circles with black tails), RNA (light blue squiggles), and various
Fig. 2. Viral proteins from HIV-1 MN exhibit protein aggregates for gp41 and p24 proteins, but not for surface protein gp120, after treatment with aryl azides+UVA for 15 min when
analyzed by Western blot for the protein of interest. Lanes: A) HIV, B) HIV+UV, C) HIV+UV+DAN, D), HIV+UV+INA. Westerns are immunostained for the proteins, as labeled;
gp41, p24, gp120 (Belanger et al., 2010).
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the wavelengths studied. Protein aggregation has been seen in other
systems involving oxidation of proteins and has been attributed to the
chemical modiﬁcation of the proteins by oxygen, and their association
via crosslinking into multimers of homoproteins (Greilberger and
Jurgens, 1998; Shoukry et al., 1994).
To further characterize the aggregation seen in Western blot
analysis, viral protein aggregation and resistance to solubilizationwith
detergent (“detergent-resistance”) was analyzed using ultracentrifu-
gation. Conditions were chosen where intact virus and aggregates of
similar density would pellet, whereas soluble proteins would not
penetrate the 25% sucrose cushion and thus remain in the supernatant.
When HIV-1 was treated with Triton X-100 (a non-ionic detergent) at
various concentrations, viral protein solubilization occurred when the
Triton concentrations were above the CMC (see Fig. 3). These data
showed that the optimal conditions for solubilization of the viruswere
above the CMC for Triton X-100 (CMC=0.021% w/v) (Coligan, 2001;
Jones et al., 1987). It was also noted that the amount of gp41 viralFig. 3. Treatment of HIV-1 above the CMC is needed for viral membrane solubilization.
HIV-1 control (no UV) samples were compared with HIV-1 treated with DAN (100 μM
with UV for 15 min) followed by Triton X-100 (0%, 0.01%, 0.1% and 1%) treatment.
Detergent-treated samples were then passed through a 25% sucrose cushion via
ultracentrifugation. The percent gp41 in the pellet was determined. Data was averaged
from two separate independent experiments using HIV lot#3592. Error bars represent
the difference between these experiments.protein that was pelleted after solubilization in Triton was increased
when the virus was pretreated with the aryl-azido compound, 1,5-
diazidonaphthalene (DAN) and UVA irradiated for 15 min (Fig. 3). The
maximal difference in the amount of pelletable gp41 protein between
untreated and DAN-treated samples, under the conditions tested,
occurred for 1% Triton X-100. This percentage was therefore chosen as
the percentage to test in subsequent experiments.
When 1% Triton was used, and the pellets and supernatants were
assayed for the viral proteins p24, gp41 and gp120, there was an
increase in the percent of some of these viral proteins in the pelleted
fraction of INA or DAN-treated samples, versus non-treated controls
(Fig. 4). This increase of pelletable material was measured using the
integration of the entire lanes for both the supernatant and pellet (as
described in Materials and methods) in the Western blot analysis to
include the integration for the aggregated and non-aggregated (“main
band”) regions for each protein. Analysis of these data for their
signiﬁcance (pb0.05) is given in Fig. 4. In theDAN-treated samples, the
percentage of gp41 and gp120 recovered in the pellet was signiﬁcantly
increased over the untreated control, whereas the percent of p24 was
not. In the INA-treated samples, however, all of the proteins tested
were signiﬁcantly increased in the pelleted fraction, with p24 and
gp41 approaching the value recovered from the non-solubilized
HIV control (Fig. 3). Additionally, the pelletable amount of all three
proteins tested was signiﬁcantly increased (pb0.05) with INA
treatment compared to DAN treatment. This increase of pelletable
material in the INA versus DAN-treated samples correlates with the
extent of protein aggregation seen in the Western blot analysis. There
is an increase in the intensity of the aggregated protein region when
INA is used versus other azido compounds (Fig. 2 and reference
(Belanger et al., 2010)). This implies that the amount of aggregation as
seen on theWestern blot analysis may be correlated with the amount
of pelletable material via sucrose cushion analysis.
Interestingly, in the case of gp41, when the main band alone was
integrated and compared between samples there was also a signiﬁcant
increase in the pelleted non-aggregated proteins (main band proteins)
indicating that the aggregated proteins are associating with, or
otherwisepromoting the pelletingof, their non-aggregated viral protein
counterparts (Fig. 4). In other words, after prolonged UV irradiation in
the presence of the aryl azide, non-aggregatedmonomeric (main band)
Fig. 4. Detergent treatment of virus after treatment with aryl-azido compounds+UVA
shows an increase in detergent-resistant pelletable material. The percent viral protein
(either gp41, p24 or gp120) in the pellet was determined after treatment with 1.0%
Triton X-100. Prior to detergent treatment, the samples were either treated with aryl
azides or were controls, as denoted below the graph. All hydrophobic compounds were
used at a ﬁnal concentration of 100 μM and irradiated with UV for 15 min. Data for each
protein was averaged from separate independent experiments using fresh HIV
lot#3602. All data is from integration of the entire lane in Western blot, except for the
gp41 “main band only” data, which represents data obtained from the integration of the
main gp41 band alone (as outlined inMaterials andmethods). Error bars represent plus
andminus two standard deviations. P-values were calculated between data sets using a
two-tailed student's T-test with unequal variances, with signiﬁcant values (pb0.05) as
denoted.
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note, because the non-aggregated proteins would be expected to most
closely represent thenativeviralproteinswhichwouldbeadvantageous
to have present in a vaccine preparation. Also, since the non-aggregated
proteins are increased in the detergent insoluble (pelleted) fraction,
these proteins would not be excluded from a preparation where
ultracentrifugation was used to purify or isolate the detergent insoluble
fraction for use in vaccine preparation.
Detergent resistance is reversed when glutathione is used during UVA
irradiation
To explore this correlation of detergent resistance as seen in the
ultracentrifugation experimentswith the aggregation seen inWestern
blot, experiments were performedwhere glutathionewas added prior
to UVA irradiation. As previously shown, the addition of glutathione
and the enzymatic depletion of oxygen prior to the UVA irradiationFig. 5. Reactive oxygen species are needed to promote viral protein aggregation and
detergent resistance. Sucrose cushion data showing the elimination of detergent
resistance by the addition of glutathione prior to irradiation. This data uses HIV-1 MN
lot #3602.step, result in the elimination of the higher molecular weight
aggregates as seen by Western blot (Belanger et al., 2010). When
samples were INA-treated and UVA-irradiated in the presence of
glutathione, they no longer maintained their detergent resistance
(Fig. 5). Similar resultswere seenwhen enzymatic depletion of oxygen
was used prior to UVA irradiation (data not shown). This result shows
that the presence of the detergent-resistant fraction depends on the
formation of ROS.
Immunoprecipitation with gp41 shows no co-immunoprecipitation of
viral proteins within detergent-resistant aggregates
Immunoprecipitation of samples that were treated with INA plus
UVA irradiation for 15 minwas performed using RIPA buffer+0.1% SDS
and anti-gp41 MAb, to assess the nature of the “detergent resistant”
aggregation. The same gp41 antibody was used for immunoprecipita-
tion as was used for the primary antibody probe via Western blot
analysis. When treated samples were immunoprecipitated using the
anti-gp41 antibody, there was no co-immunoprecipitation of gp120,
p17orp24, although the gp41proteinaggregates remained (Fig. 6A, p24
not shown). This suggests that the higher molecular weight smear of
gp41 is due to gp41–gp41 interactions and possibly other protein–gp41
interactions involving other proteins on the virus that were not tested.
Furthermore, since these aggregates could not be removed with 0.1%
SDS and RIPA buffer (which contains 0.25% deoxycholic acid and 1%
NP-40), it is possible that these interactions are covalent in nature.
Immunoprecipitation using neutralizing antibodies shows preservation
of neutralization epitopes after Triton treatment
Previous studies have shown that treatment of HIV-1 with INA or
DAN plus UV for 15 min does not damage key neutralizing epitopes
(Belanger et al., 2010). Herein, an additional immunoprecipitation
experiment was performed using broadly neutralizing antibodies
(NAbs) to assess whether or not these antibodies could still recognize
the neutralization epitopes after the additional step of Triton treatment,
of the aryl-azide ROS-modiﬁed-virus. For this experiment, 1% Triton X-
100 was used to lyse the virus after treatment with aryl azide, followed
by binding of either an anti-gp41 NAb (“4E10”) or anti-gp120 NAb
(“2g12”) and subsequent capture by protein G dynabeads. Attempts
were made to ﬁrst pellet the Triton-treated virus prior to NAb binding,
but resuspension of the aryl-azide+Triton-treated viral pellet was
difﬁcult (as could be seen by eye) and led to irreproducible results. The
data obtained for the Triton-treated suspensions, without pelleting, is
shown in Fig. 7. In the HIV control (without UV irradiation), 1% Triton
treatment does not disrupt recognition of gp120 by2g12, nor of gp41 by
4E10 (Fig. 7, lanes C andD, respectively). Furthermore, Triton treatment
of the control does not disrupt the gp41–gp120 association. Treatment
with INA+UV for 15 min, followed by 1% Triton shows that there is
some preservation of both 4E10 and 2g12 epitopes. Quantitative
analysis of this data was not performed, however, it can be seen that
the intensity of the bands from the INA-treated virus are diminished
compared to the controls, suggesting that some damage to the epitopes
may have taken place during this combined treatment of aryl azide+
Triton. Although damage to the epitopes may have occurred, 4E10
appears to immunoprecipitate the gp41 aggregates, suggesting that
either the epitope is still present in the aggregated region or that the
aggregated region is otherwise associatedwith a fraction containing the
epitope. Interestingly, in the case of the INA-treated virus plus Triton, it
is seen that immunoprecipitation with 4E10 does not co-IP gp120, as it
did in the control. This may be due to the INA-treated virus being more
prone to gp120 shedding upon binding of 4E10. In support of this
hypothesis, it has been previously noted that binding of 4E10 and
similar antibodies promotes gp120 shedding, the extent of which may
be virus strain dependent (Ruprecht et al., 2011). These data provide
evidence that although some damage of epitopes may have occurred,
Fig. 6. Immunoprecipitation using anti-gp41 in RIPA buffer+0.1% SDS, shows stable aggregation for gp41. Gp41 aggregates remain after IP using anti-gp41 but do not contain gp120,
p17, or p24 (not shown). A, B, and C are non-immunoprecipitated controls, where A=HIV control, B=HIV+DMSO+UV 15 min, C=HIV+INA+UV irradiation 15 min; D, E are
immunoprecipitated samples using anti-gp41 and dynal beads with samples where, D=HIV+DMSO+UV irradiation 15 min, E=HIV+INA+UV irradiation 15 min; and F and G
are mock immunoprecipitated samples, using treated HIV samples with Dynal beads and no antibody. Westerns probed using antibodies noted below the blot image, with secondary
antibodies described in Materials and methods. Blots shown are representative samples of experiments done in duplicate.
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preparations, which is advantageous for the use of this method towards
vaccine preparation. Further optimization and characterization is still
needed to assess preservation or destruction of additional epitopes,
including those that may be novel to the aryl-azide+Triton-treated
virus preparation.
TEM analysis of pelleted viral protein indicates overall virus structure is
no longer intact
TEM analysis was performed on samples treated with aryl azides
under conditions where ROS-induced viral protein aggregation
occurred, followed by detergent treatment, and pelleting of the viral
lysates. TEM studies of similar preparations and controls indicate that
the overall virus structure after Triton treatment is damaged, but
fragments of virus are still intact (see Fig. 8). HIV virions with
damaged envelope that are reminiscent of intact virions can be seen,
even after detergent treatment.
Similar studies using Vesicular Stomatitis and Sindbis viruses show
that treatment with formaldehyde or gluteraldehyde (common
ﬁxation techniques) followed by detergent (SDS) also resulted in an
increase in the pelletable fraction of viral proteins, with the resulting
virus appearing as a shell of viral proteins in TEM (Brown et al., 1974).
However, ﬁxation can cause damage to surface epitopes in treatedFig. 7. Immunoprecipitation (IP) of HIV-1 treatedwith INA plus UV irradiation, followed by
Triton treatment partiallymaintains two key neutralizing epitopes. Viruswas either treated
with INAplusUVA for 15 min, or left untreated, followed by treatmentwith 1% TritonX-100
for 1 h at room temperature prior to IP using neutralizing antibodies 2g12 and 4E10.
Westernblottingusinganti-gp41andanti-gp120 (ranonseparate blots) as shown.A)HIV-1
before IP (no Triton), B)HIV+beads only, C)HIV+2g12, D)HIV+4E10, E)HIV+INA+UV
15 min+beads only, F) HIV+INA+UV 15 min+2g12, G)HIV+INA+UV 15 min+4E10.
Heavy (H) chain from the immunoprecipitating antibody is also present.viruses. Our strategy, using ROS-induced protein aggregation promot-
ed via aryl azide reactions, has been shown to preserve surface
epitopes and also has the unique advantage that the reaction to
generate the aggregates is dependent on the external inﬂuence of UVA
irradiation (Belanger et al., 2010). Conversely, treatmentwithﬁxatives
usually requires additional chemical treatment and puriﬁcation steps
to scavenge any unreacted aldehydes. Although TEM indicates that the
whole virons are damaged, it does support that there are intact viral
fragments remaining. This TEM data combined with the aforemen-
tioned pelleting data (Fig. 3), supports the hypothesis that the pelleted
viral lysate of the aryl-azido treated virus contains more viral proteins
than the pellet from the lysate of the infectious control.
Towards the generation of a novel orthogonally inactivated virus vaccine
strategy
Using aryl-azides and UVA irradiation to inactivate enveloped
viruses under conditions to create detergent-resistant viral protein
aggregates through reactive oxygen species, provides a novelmeans for
the production of an orthogonally inactivated virus preparation. This
preparation has the unique advantage that the inactivated virions are
partially detergent resistant, while any “missed” virions (such as those
present in clumps or on walls of the treatment vessel) that may still be
infectious are detergent sensitive. Thus, combining aryl-azide+UVA
treatment, with a subsequent detergent treatment step, provides a
means for the orthogonal inactivation of enveloped viruses towards the
15 logs of inactivation proposed (Schultz et al., 1990) for an inactivated
virus vaccine to be safely considered. Furthermore, the generation of
detergent-resistant viral fragments that contain key viral proteins may
provide an advantage over traditional split virus vaccine strategies (see
Fig. 1), by potentially presenting unique epitopes preserved from the
native virion structure to the immune system. It has been shown in vitro
that someneutralizing epitopes are at least partially intact in the treated
HIV-1 virus, which is desirable towards the application of this method
for the generation of vaccines. Further development and optimization of
this method, including in vivo characterization against known vaccines
is still needed, but this study provides a promising starting point for this
novel strategy.
Conclusions
Preparation of inactivated virus vaccines using photoactivatable
aryl-azido compounds can be used not only for the preparation of
inactivated whole virus vaccines, but can also be used towards the
generation of a novel class of orthogonally inactivated virus vaccines.
Prolonged UVA irradiation in the presence of aryl azides, such as
Fig. 8. Transmission electron microscopy (TEM) images of pelleted HIV after Triton treatment show virions and viral protein aggregates remaining after Triton treatment. Samples were
treated as speciﬁedwith eitherDANor INA then treatedwith 1%TritonX-100 at room temperature for 1 h before pelleting through25% sucrose, and TEManalysis. A) andD) are controls of
HIV andHIV+DAN+UVA for 15 min, respectively; B and C areHIV controls+Triton treatmentwith either 0.1% or 1%Triton as speciﬁed; E–Hare images of virus treatedwithDAN+UVA
for 15 min, or INA+UVA for 15 min, with either 0.1% or 1% Triton treatment, as speciﬁed. Arrows indicate: Vsc = microvesicle, V = HIV virion. Scale bars are 200 nm.
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aggregation, without damage to surface epitopes, which persisted even
in the presence of detergent. This can be used towards an orthogonal
inactivation technique whereby infectious material is rendered non-
infectious through photoactivation of aryl azides, with further irradia-
tion to induce ROS species, followed by detergent treatment. The
detergent treatment step provides a “mop-up” to remove any residual
untreated infectious virus, while the treated virus, although no longer
whole, maintains pelletable detergent-resistant aggregates, hypothe-
sized to represent epitopes similar to those found in the native intact
virus. Further studies are ongoing to characterize this effect in other
viruses, such as inﬂuenza, and to compare this novel orthogonal
inactivation strategy versus conventional chemical inactivation tech-
niques for vaccine preparation, in animal studies.Materials and methods
Safety
All handling of infectious HIV-1 isolates were done under Biosafety
Level 2 conditions, following Biosafety Level 3 procedures, with the
proper personal protective equipment. Synthesis and handling of the
azido compounds was performed using the proper precautions due to
the potentially explosive nature of these compounds.Reagents
The azido-containing compound, 1,5-diazidonapthalene (DAN)
was made according to previously published procedures (Belanger
et al., 2010). 1,5-Iodonaphthylazide (INA) was custom-synthesized by
Biotium (Hayward, CA). HIV-1 MN cl. 4 concentrated virus stock (lots
#P3592 and #P3602) was prepared by the AIDS Vaccine Program,
SAIC (Chertova et al., 2002). The anti-gp41 monoclonal antibody was
puriﬁed from the hybridoma for Chessie 8 from Dr. George Lewis,
obtained through the ARRRP. The anti-gp120 (ID6) monoclonal
antibody used for Western blots, was obtained through the ARRRP
fromDr. Kenneth Ugen and Dr. DavidWeiner. The anti-p24 (183-H12-
5C) monoclonal antibody used for Western blot was obtained from
the ARRRP, from Dr. Bruce Chesebro and Kathy Wehrly. Secondary
antibody used for Western analysis and the quantitation of pelleted
proteins was Alexaﬂuor680 goat anti-mouse IgG (Invitrogen) using an
Odyssey infrared imaging system and software for lane integration.
Secondary antibody of donkey anti-goat Alexaﬂuor 800 (Invitrogen)
was used for Western analysis when the polyclonal anti-p17 goat
antibody (antisera from the AIDS and Cancer Virus Program, NCI-
Frederick) was used. Anti-HIV-1 broadly neutralizing antibodies 2G12
and 4E10 were from Herman Katinger through the ARRRP. Triton X-
100 (Surfact-Amps, ampules of 10% solution in water, cat#PI-28314)
was used for the detergent treatment of viruses. Sucrose (RNase-free,
cat#S9378) was obtained from Sigma-Aldrich.
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Treatment of HIV-1 with the compounds was done according to
previously published procedures (Belanger et al., 2010). In brief, each
compound was added (from 8 mM stock in DMSO) to a diluted
suspension of HIV-1 MN (0.5 mg/mL total protein in PBS) for a ﬁnal
concentration of 100 μM of compound. The viral suspension was then
irradiated with UVA light for 15 min. Sample volumes used for
irradiation varied from 0.10 mL to 1.0 mL in clear polypropylene
microfuge tubes. For samples that were treated with glutathione prior
to irradiation, INA was added to the HIV-1 as described, followed by
the addition of glutathione for an end concentration of 20 mM (from a
stock solution of 1.0 M glutathione in PBS, pH=7.4).
Western blot analysis for protein aggregation
HIV-1 samples treated with azido compound plus UV irradiation
and controls were lysed in SDS sample buffer (Laemmli) under
reducing conditions for 15–20 min at 55–60 °C. Aliquots of these were
added to a 4–20% Tris–glycine gel. SDS-PAGE was performed and the
proteins were transferred to a nitrocellulose membrane and detected
using either monoclonal or polyclonal antibodies as speciﬁed.
Secondary antibodies containing AlexaFluor680 (either goat anti-
mouse for the murine primary antibodies or donkey anti-goat for the
goat primary antibody) were used for readout on an Odyssey Infrared
Imaging System (LiCOR Biosciences). Stripping of the blots was not
done; instead, a new blot was done for each antibody probe used.
Detergent treatment of HIV
Triton X-100 in PBS (10 μL) was added to aliquots of HIV-1 MN
(90 μL) that had been treated with aryl azide+UV, or controls,
containing 0.5 mg/mL total protein (prepared as described above) for
a ﬁnal Triton concentration of either 0.01%, 0.1% or 1%, and a ﬁnal
protein concentration of 0.45 mg/mL. Mock-treated samples were
made with PBS. Samples were brieﬂy mixed by pipette, and then
allowed to sit at room temperature, in the dark, for 1 h. Triton was not
removed from the samples prior to analysis.
Sucrose cushion and pelleting of detergent-treated virus with Western
blot analysis
For the analysis of the detergent insoluble fraction, detergent-treated
and control samples were pelleted via ultracentrifugation through 25%
sucrose to separate out the soluble and insoluble fractions. 200 μL of 25%
sucrose (in PBS) was placed into a polycarbonate ultracentrifuge tube
(Beckman #343776, 8 mm×34 mm). To this, 90 μL of detergent-treated
sample (or control)was carefully added (undiluted) on topof the sucrose
cushionwith caution tomaintain the phase boundary. The sampleswere
then ultracentrifuged (Optima TLX tabletop ultracentrifuge) in a ﬁxed-
angle rotor (TLA 120.1) at 45,000 rpm for 30 min at 15 °C. Immediately
after centrifugation, the supernatant (290 μL total) was carefully
removed and added to SDS sample buffer (Laemmli) under reducing
conditions (4×) in a microfuge tube. To the remaining pellet, still in the
centrifuge tube, was added 290 μL of PBS and sample buffer. Pellets were
very sticky after centrifugation so care was needed to resuspend them in
the sample buffer by aspirating gentlywith a pipette tip andpipettor. The
entire centrifuge tube, with pellet solution, was placed into a larger 2 mL
microfuge tube with a lid, and stored that way. Both supernatant and
pellet solutions were stored at−20 °C overnight. The following day, the
samples were heated at 60 °C for 15–20 min and SDS-PAGE was run
(Invitrogen, Tris–glycine gels, 10-well, 4–20%). The gels were blotted
onto nitrocellulose and probed via Western blot using MAbs for the
proteins of interest, and Alexaﬂuor 680 conjugatedMouse IgG secondary
antibody for IR readout and integrationusing anOdyssey imaging system
and software. Separate lanes for the pellet (P) solution and supernatant(S) solutionwere run for each sample on the samegel. Integrationof each
of these lanes was done using the Odyssey software and each lane was
selected to determine the raw integrated intensity of the entire lane. The
entire lane was selected to include all the protein aggregates that
contained the probed protein of interest, and the entire lanes were
integrated in the controls as well for direct comparison. For data labeled
as “main band only”, only the main protein band (no aggregates) was
integrated. The “percent in pellet” (%P)was then determined using these
raw integrated intensities as follows: %P=P/(P+S), where P and S are
the respective entire lane integrations of thepellet and supernatant lanes
for one sample. Separate gels were run for each protein of interest to be
probed via Western blot; Western blots were not reprobed.
TEM of detergent-treated HIV
Detergent-treated HIV samples were prepared as outlined above
using a sucrose cushion. The supernatant was removed and to the
remaining pellet was added 100 μL of PBS, followed by ultracentrifu-
gation at 40,000 rpm for 10 min. The PBS was removed and another
PBS “wash” followed by centrifugation was performed, to remove
residual sucrose. After the second wash, 200 μL of ﬁxative (2%
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2 solution) was
added to the pellet, allowed to sit at room temperature for 1 h, and
then stored at 4 °C until TEM analysis was performed. The pellet was
post ﬁxed in 1% osmium tetroxide in the same buffer for 1 h. The pellet
was dehydrated in ethanol (e.g., 35%, 50%, 75%, 95%, 100%) and 100%
propylene oxide. The pellet was inﬁltrated overnight in 1:1 mixture of
propylene oxide and epoxy resin, and embedded in a pure resin and
cured for 48 h in 55 °C. The 70 nm thin sections were made and
mounted on naked copper grids. The thin sectionswere double stained
(uranyl acetate and lead citrate), examined in a Hitachi (Tokyo, Japan)
H-7600 transmission electron microscope, and the images were taken
using an AMT (Danvers, MA) digital camera.
Immunoprecipitation of HIV in RIPA+SDS buffer
Samples of HIV (0.5 mL of 0.5 mg/mL) were treated with 100 μM INA
followed by UVA irradiation for 15min (as outlined above). Control
samples with DMSO+UVA for 15 min were also prepared. To these
samples, after irradiation, was added protease inhibitor (Complete Mini
Protease Inhibitor, Roche) and RIPA lysis buffer (Upstate Cell Signaling
Solutions, Cat#20-188) for a ﬁnal 1× concentration of each, plus SDS
(BioRad 20% solution, cat#161-0418) was added for a ﬁnal concentration
of 0.1%SDS. Sampleswerebrieﬂyvortexed, and thenplacedona rotator at
room temperature for 2 h to lyse the samples. During this time, protein G
Dynabeads (Invitrogen, cat#100.03D) with immobilized antibody were
prepared. To a clean microfuge tube was added 50 μL of dynabeads, a
magnet was applied and the liquid removed. To this was added 20 μL of
anti-gp41 antibody diluted to 200 μL in PBS. The beadswere resuspended
and incubated at room temperature with rotation for 30 min. Subse-
quently, the beadswerewashedwith PBS three times and resuspended in
a 25 mM dimethyl pimelimidate (DMP, ThermoFisher, cat#21667)
solution containing triethanolamine, pH=8.0, to crosslink the antibodies
to the beads. Beadswere incubated at room temperaturewith rotation for
1 h, and thenwashed 3 timeswith 200 μL of 0.2 M glycine–HCl, pH=2.5,
to remove any non-crosslinked antibody. The beads were then washed
with PBSuntil the supernatantwaspH=7.4, followedbywashing2 times
with the same buffer used to lyse the HIV (RIPA 1×, Protease Inhibitor 1×,
0.1%SDS).After the2 hour incubationof the lysedHIVabove, 250 μLof the
lysed HIV sample was added to the beads. Another 250 μL of the lysed
sample was added to beads that had been mock-treated (through all the
same steps above), without the addition of the anti-gp41 antibody, to
assess background binding of HIV to the beads. In total, 6 samples were
prepared; HIV+INA+UV 15min+beads±antibody; HIV+DMSO+
UV 15min+beads±antibody; beads mock-treated without addition of
HIV±antibody. The last twocontrolswere to account for anynon-speciﬁc
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Westernblot analysis. After additionof the lysed (ormock) samples to the
beads, thebeadswere incubated for30 min,washed three timeswith lysis
buffer, beads and sup were transferred to a new microfuge tube, and
washed onemore timewith plain PBS. The beadswere then resuspended
in 100 μL of 1× Laemmli reducing sample buffer and heated at 60 °C for
15 min to recover the immunoprecipitated proteins. A magnet was
applied to remove thebeads, andWesternblot analysiswasperformedon
the sample for the HIV proteins of interest. Antibodies used for the
Western blot were as follows: Cleanblot HRP (Thermoscientiﬁc,
cat#21230) (used as secondary when primary Ab of anti-p17 was
used), and Trueblot HRP (eBioscience, cat#18-8877-33) (used as
secondary when primary Ab of anti-gp120 or anti-gp41 were used).
HRP-probed blots were developed using an ECL Western Blotting
substrate (Pierce, cat#32209) and ﬁlm.Immunoprecipitation of HIV using neutralizing antibodies
HIV (0.30 mL of 0.5 mg/mL)was treatedwith 100 μM INA followed
by UVA irradiation for 15 min (as outlined above). HIV control sample
without DMSO or irradiationwas also prepared. To these samples, was
added Triton X-100 (from 10× stock containing protease inhibitor
(Complete Mini Protease Inhibitor, Roche)) for a ﬁnal Triton X-100
concentration of 1%. Samples were brieﬂy vortexed, and then
incubated at room temperature for 1 h. After 1 h, the sample was
divided into 100 μL aliquots and treated with one of the following:
10 μL PBS (mock), 10 μL of 1 mg/mL 2g12 antibody, and 10 μL of 4E10
antibody. All six samples were incubated overnight at room temper-
ature with rotation. The following day, Dynabeads (washed 2 times in
equal volume of 1% Triton X-100 with protease inhibitor) were added
to each sample (1 mg beads per 100 μL sample) and rotated for 1 h.
After this incubation, amagnetwas applied, supernatant was removed
and the beads were washedwith 1% Triton X-100+protease inhibitor
(twice) and PBS+protease inhibitor (twice), with gentle resuspen-
sion and application of magnet between washings. After the ﬁnal
washing step, the beads were resuspended in PBS and transferred to a
new tube. A magnet was applied, supernatant was removed, and to
each sample 60 μL Laemmli reducing sample buffer (1×) was added.
Sampleswere heated at 70 °C for 15–20 min before running SDS-PAGE
and subsequent Western. Blots were probed with either anti-gp41
(Chessie 8) or anti-gp120 (ID6) followed by Trueblot Biotin secondary
antibody (ebioscience, cat#13-88717-82) and Streptavidin Alexaﬂuor
800 (Odyssey IRdye, cat#926-32210), with readout performed on an
Odyssey Infrared Imaging system.Acknowledgments
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